Safety and Efficacy of ABP-745 in Participants With an Acute Gout Flare
NCT07145229
This study is recruiting at 11 US sites in 9 states, according to its ClinicalTrials.gov record last updated .
Summary
A randomized, double-blind, international multicenter, colchicine and placebo-controlled study to evaluate the efficacy and safety of ABP-745 in subjects with acute gout. Efficacy of ABP-745 in reducing pain and swelling compared with standard colchicine treatment and placebo will be evaluated in participants with acute gout. The primary efficacy measurement will be pain score after treatment.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Acute Gouty Arthritis
- Gout Flare
- Gout Flares
- Acute Gout Flare
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Atom Therapeutics Co., Ltd
- Last updated on ClinicalTrials.gov
- December 8, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arizona · 1
- Onyx Clinical Research · Peoria, AZ
California · 1
- Exinia Research · La Mesa, CA
Illinois · 1
- Bioluminux Clinical Research · Naperville, IL
Iowa · 1
- Exinia Research · Des Moines, IA
Louisiana · 3
- Northshore Research Associates · Alexandria, LA
- DelRicht Research · Baton Rouge, LA
- DelRicht Research · New Orleans, LA
Maryland · 1
- Interphase Clinical Trials · Lutherville, MD
Mississippi · 1
- DelRicht Research Gulfport · Gulfport, MS
New Mexico · 1
- Albuquerque Clinical Trials, Inc. · Albuquerque, NM
Oklahoma · 1
- DelRicht Research · Tulsa, OK
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.